These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 18607863

  • 1. Dose intensity comparison between weekly and 3-weekly Cisplatin delivered concurrently with radical radiotherapy for head and neck cancer: a retrospective comparison from New Cross Hospital, Wolverhampton, UK.
    Ho KF, Swindell R, Brammer CV.
    Acta Oncol; 2008; 47(8):1513-8. PubMed ID: 18607863
    [Abstract] [Full Text] [Related]

  • 2. The comparison of acute toxicity in 2 treatment courses: Three-weekly and weekly cisplatin treatment administered with radiotherapy in patients with head and neck squamous cell carcinoma.
    Mackiewicz J, Rybarczyk-Kasiuchnicz A, Łasińska I, Mazur-Roszak M, Świniuch D, Michalak M, Kaźmierska J, Studniarek A, Krokowicz Ł, Bajon T.
    Medicine (Baltimore); 2017 Dec; 96(51):e9151. PubMed ID: 29390445
    [Abstract] [Full Text] [Related]

  • 3. Weekly and 3-weekly cisplatin concurrent with intensity-modulated radiotherapy in locally advanced head and neck squamous cell cancer.
    Espeli V, Zucca E, Ghielmini M, Giannini O, Salatino A, Martucci F, Richetti A.
    Oral Oncol; 2012 Mar; 48(3):266-71. PubMed ID: 22079100
    [Abstract] [Full Text] [Related]

  • 4. A comparison of weekly versus 3-weekly cisplatin during adjuvant radiotherapy for high-risk head and neck cancer.
    Oosting SF, Chen TWW, Huang SH, Wang L, Waldron J, Gilbert R, Goldstein D, Halmos GB, Witjes MJH, Gietema JA, O'Sullivan B, Langendijk JA, Siu LL, Hansen AR.
    Oral Oncol; 2016 Aug; 59():43-49. PubMed ID: 27424181
    [Abstract] [Full Text] [Related]

  • 5. Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.
    Szturz P, Wouters K, Kiyota N, Tahara M, Prabhash K, Noronha V, Castro A, Licitra L, Adelstein D, Vermorken JB.
    Oncologist; 2017 Sep; 22(9):1056-1066. PubMed ID: 28533474
    [Abstract] [Full Text] [Related]

  • 6. Concomitant cisplatin, paclitaxel, and hyperfractionated radiotherapy in locally advanced head and neck cancer: comparison of two different schedules.
    Moreno-Jiménez M, Valero J, López-Picazo JM, Arbea L, Aristu J, Cambeiro M, Alcalde J, Martínez-Monge R.
    Am J Clin Oncol; 2010 Apr; 33(2):137-43. PubMed ID: 19786847
    [Abstract] [Full Text] [Related]

  • 7. Accelerated fractionation radiotherapy and late intensification with 2 intra-arterial cisplatin infusions for locally advanced head and neck squamous cell carcinoma.
    Yu KH, Yu SC, Hui EP, Kam MK, Vlantis AC, Yuen E, Chan AT.
    Head Neck; 2010 Jul; 32(7):913-20. PubMed ID: 19885925
    [Abstract] [Full Text] [Related]

  • 8. Acute toxicity of three versus two courses of cisplatin for radiochemotherapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN): a matched pair analysis.
    Rades D, Kronemann S, Meyners T, Schild SE, Hakim SG.
    Oral Oncol; 2010 Jul; 46(7):549-52. PubMed ID: 20435508
    [Abstract] [Full Text] [Related]

  • 9. Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
    Katori H, Tsukuda M, Watai K.
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):399-406. PubMed ID: 17096160
    [Abstract] [Full Text] [Related]

  • 10. Dose-finding study of docetaxel added to ifosfamide and cisplatin followed by concomitant capecitabine and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck.
    Recchia F, Saggio G, Cesta A, Amiconi G, di Blasio A, Candeloro G, Valeriani M, Tombolini V, Rea S.
    Anticancer Res; 2006 Aug; 26(3B):2317-24. PubMed ID: 16821609
    [Abstract] [Full Text] [Related]

  • 11. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.
    Brizel DM, Murphy BA, Rosenthal DI, Pandya KJ, Glück S, Brizel HE, Meredith RF, Berger D, Chen MG, Mendenhall W.
    J Clin Oncol; 2008 May 20; 26(15):2489-96. PubMed ID: 18487568
    [Abstract] [Full Text] [Related]

  • 12. Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naïve locally advanced upper aerodigestive malignancy.
    Langer CJ, Duffy K, Horwitz EM, Litwin S, Rosvold E, Schol J, Keenan E, Nicolaou N, Friedman CD, Ridge JA.
    Cancer Invest; 2006 Mar 20; 24(2):164-73. PubMed ID: 16537186
    [Abstract] [Full Text] [Related]

  • 13. The comparison of weekly and three-weekly cisplatin chemotherapy concurrent with radiotherapy in patients with previously untreated inoperable non-metastatic squamous cell carcinoma of the head and neck.
    Uygun K, Bilici A, Karagol H, Caloglu M, Cicin I, Aksu G, Fayda M, Uzunoglu S.
    Cancer Chemother Pharmacol; 2009 Aug 20; 64(3):601-5. PubMed ID: 19123002
    [Abstract] [Full Text] [Related]

  • 14. Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas.
    Prestwich RJ, Öksüz DÇ, Dyker K, Coyle C, Şen M.
    Int J Radiat Oncol Biol Phys; 2011 Nov 15; 81(4):e237-43. PubMed ID: 21620580
    [Abstract] [Full Text] [Related]

  • 15. Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study.
    Ghi MG, Paccagnella A, D'Amanzo P, Mione CA, Fasan S, Paro S, Mastromauro C, Carnuccio R, Turcato G, Gatti C, Pallini A, Nascimben O, Biason R, Oniga F, Medici M, Rossi F, Fila G.
    Int J Radiat Oncol Biol Phys; 2004 Jun 01; 59(2):481-7. PubMed ID: 15145166
    [Abstract] [Full Text] [Related]

  • 16. Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma.
    Fayette J, Molin Y, Lavergne E, Montbarbon X, Racadot S, Poupart M, Ramade A, Zrounba P, Ceruse P, Pommier P.
    Drug Des Devel Ther; 2015 Jun 01; 9():6203-10. PubMed ID: 26648696
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and tolerability of weekly low-dose cisplatin concurrent with radiotherapy in head and neck cancer patients.
    Otty Z, Skinner MB, Dass J, Collins M, Mooi J, Thuraisingam K, Sabesan S.
    Asia Pac J Clin Oncol; 2011 Sep 01; 7(3):287-92. PubMed ID: 21884441
    [Abstract] [Full Text] [Related]

  • 18. Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck.
    Schwartz DL, Montgomery RB, Yueh B, Donahue M, Anzai Y, Canby R, Buelna R, Anderson L, Boyd C, Hutson J, Keegan K.
    Cancer; 2005 Jun 15; 103(12):2534-43. PubMed ID: 15856475
    [Abstract] [Full Text] [Related]

  • 19. Randomized phase II trial of concomitant chemoradiotherapy using weekly carboplatin or daily low-dose cisplatin for squamous cell carcinoma of the head and neck.
    Homma A, Shirato H, Furuta Y, Nishioka T, Oridate N, Tsuchiya K, Nagahashi T, Aoyama H, Inuyama Y, Fukuda S.
    Cancer J; 2004 Jun 15; 10(5):326-32. PubMed ID: 15530262
    [Abstract] [Full Text] [Related]

  • 20. Weekly cisplatin with radiotherapy for locally advanced head and neck squamous cell carcinoma.
    Sautois B, Schroeder H, Martin M, Piret P, Demez P, Bouchain O, Mutijima E, Moreau P.
    J BUON; 2016 Jun 15; 21(4):979-988. PubMed ID: 27685923
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.